Bernstein Maintains Outperform on Medline, Lowers Price Target to $54

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

Bernstein analyst Lee Hambright maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $56 to $54.